Skip to main content
. 2019 Apr 16;4(7):987–994. doi: 10.1016/j.ekir.2019.04.010

Figure 1.

Figure 1

Efficacy of etelcalcetide (ETEL) at attaining laboratory targets for (a) intact parathyroid hormone (PTH) >30% reduction, (b) PTH ≤ 300 pg/ml, (c) P < 5.5 mg/dl, and (d) both PTH ≤ 300 pg/ml and P < 5.5 mg/dl, during the efficacy-assessment phase (EAP). Patients with no PTH and/or P measurement during the EAP were considered as not achieving the endpoint. PBO, placebo; P, phosphate.